sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis
Macrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and Fibrosis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Aarhus, Denmark, 8000
- Department of Hepatology and Gastroenterology, Aarhus University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosed with Wilsons disease
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Wilsons disease
All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.
|
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver.
The fibroscan is a non-invasive procedure
Ultrasound is a non-invasive procedure
Galactose elimination capacity is performed to evaluate metabolic liver function. The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
Other Names:
Histological disease activity at time of diagnosis evaluating if any liver fibrosis
Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measurement of the macrophage activation markers sCD163
Time Frame: Baseline, 1 year, 2 year, 3 year
|
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.
|
Baseline, 1 year, 2 year, 3 year
|
|
Measurement of soluble mannose receptor (sMR)
Time Frame: Baseline, 1 year, 2 year, 3 year
|
For the investigations a total of 100 ml of blood is drawn, all stored in a research biobank.
|
Baseline, 1 year, 2 year, 3 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Urinary copper excretion in 24 hour urine collection
Time Frame: Baseline, 1 year, 2 year, 3 year
|
The patient collects urine for 24 hours at home in a designated container, which is handed out at the department.
The container is kept refrigerated and is brought to the control
|
Baseline, 1 year, 2 year, 3 year
|
|
Ultrasound is performed for signs of liver cirrhosis.
Time Frame: Baseline, 1 year, 2 year, 3 year
|
Ultrasound is a non-invasive procedure.
Signs og liver cirrhosis by ultrasound are surface modularity, a smaller liver, heterogeneous echo texture and signs of portal hypertension.
|
Baseline, 1 year, 2 year, 3 year
|
|
Fibroscan is performed to evaluate liver stiffness (fibrosis)
Time Frame: Baseline, 1 year, 2 year, 3 year
|
Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver.
The fibroscan is a non-invasive procedure.
|
Baseline, 1 year, 2 year, 3 year
|
|
Continous Reaction Time to evaluate brain dysfunction
Time Frame: Baseline, 1 year, 2 year, 3 year
|
Continous Reaction Time is a computerized 10 minutes test that measures and combines motor reaction speed and sustained attention.
|
Baseline, 1 year, 2 year, 3 year
|
|
Galactose elimination capacity is performed to evaluate metabolic liver function
Time Frame: Baseline, 1 year, 2 year, 3 year
|
The metabolic liver function test Galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours.
|
Baseline, 1 year, 2 year, 3 year
|
|
Histological disease activity at time of diagnosis and liver biopsy, evaluating if any liver fibrosis
Time Frame: Baseline, 1 year, 2 year, 3 year
|
Liver fibrosis will be also be determined on liver biopsies.
|
Baseline, 1 year, 2 year, 3 year
|
|
Functional hepatic nitrogen clearance to evaluate metabolic liver function
Time Frame: Baseline, 1 year, 2 year, 3 year
|
Functional hepatic nitrogen clearancerequires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours.
It evaluates the metabolic liver function by measuring the clearance of alanine from blod by analyzing the amount og urea in the urine collected 4 hours after the start og the alanine infusion.
|
Baseline, 1 year, 2 year, 3 year
|
|
The Portosystemic Encephalopathy to evaluate brain dysfunction
Time Frame: Baseline, 1 year, 2 year, 3 year
|
The Portosystemic Encephalopathy test is a 15-minute paper-pencil test battery comprised of 5 sub-tests: Digit Symbol test (DST), Number Connection Test A (NCT-A), Number Connection Test B (NCT-B), Serial Dotting Test (SDOT), and Line Tracing Test (LTT, time and errors).
|
Baseline, 1 year, 2 year, 3 year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Henning Grønbæk, Professor, Aarhus University Hospital, Nørrebrogade 44, Aarhus C, Denmark, 8000
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Liver Diseases
- Genetic Diseases, Inborn
- Basal Ganglia Diseases
- Movement Disorders
- Neurodegenerative Diseases
- Metabolism, Inborn Errors
- Heredodegenerative Disorders, Nervous System
- Brain Diseases, Metabolic
- Brain Diseases, Metabolic, Inborn
- Metal Metabolism, Inborn Errors
- Hepatolenticular Degeneration
Other Study ID Numbers
Other Study ID Numbers
- Wilson sCD163
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.